<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00901186</url>
  </required_header>
  <id_info>
    <org_study_id>CRFB002DES01</org_study_id>
    <secondary_id>2009-010825-37</secondary_id>
    <nct_id>NCT00901186</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Ranibizumab (Intravitreal Injections) Versus Laser Treatment in Patients With Visual Impairment Due to Diabetic Macular Edema</brief_title>
  <acronym>RED-ES</acronym>
  <official_title>A Randomized, Open Label, Multicenter, Laser-controlled Phase II Study Assessing the Efficacy and Safety of Ranibizumab (Intravitreal Injections) vs. Laser Treatment in Patients With Visual Impairment Due to Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess the efficacy and safety of ranibizumab (intravitreal injections)
      versus laser treatment in patients with visual impairment due to diabetic macular edema.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Visual acuity (VA) was assessed on the study eye during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Improvement in BCVA</measure>
    <time_frame>12 months</time_frame>
    <description>Visual acuity (VA) was assessed on the study eye during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Mean Change From Baseline in BCVA by Study Visit</measure>
    <time_frame>Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12</time_frame>
    <description>Visual acuity (VA) was assessed on the study eye during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With VA &gt; 73 Letters With Ranibizumab (0.5 mg) vs Laser.</measure>
    <time_frame>12 months</time_frame>
    <description>VA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Central Retinal Thickness (CRT) by Study Visit</measure>
    <time_frame>Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12</time_frame>
    <description>CRT was assessed by Optical Coherence Tomography (OCT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of CRT Change From Baseline by Study Visit</measure>
    <time_frame>Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12</time_frame>
    <description>CRT was assessed by Optical Coherence Tomography (OCT).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <condition>Visual Impairment</condition>
  <arm_group>
    <arm_group_label>RFB002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RFB002 0.5 mg was administered to the study eye with a single monthly intravitreal injection on day 1, day 30 and day 60. After day 90, if stable vision was not achieved, a monthly injection of RFB002 0.5 mg was administered until stable vision was achieved.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laser photocoagulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At least one treatment of laser photocoagulation was applied on day 1. The maximum number of laser photocoagulation treatments was 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RFB002</intervention_name>
    <description>0.5 mg</description>
    <arm_group_label>RFB002</arm_group_label>
    <other_name>Ranibizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laser photocoagulation</intervention_name>
    <arm_group_label>Laser photocoagulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diabetes mellitus 1 or 2, HbA1c &lt; 11.0%, With: Clinically significant Diabetic Macular
             Edema in at least one eye.

          2. Previous treatment with macular photocoagulation only should be considered if the
             investigator believes that the study eye may possibly benefit from additional
             photocoagulation.

          3. Best corrected visual acuity score between 78 and 25 letters (Early Treatment Diabetic
             Retinopathy Study- ETDRS Chart - 4 meters).

          4. Central foveal thickness &gt;250µm (Optical Coherence Tomography).

          5. Diabetes medication stable in the 3 months prior.

        Exclusion Criteria:

        In the study eye:

          1. Active intraocular inflammation.

          2. Any active infection.

          3. History of uveitis.

          4. Structural damage within 500 microns of the center of the macula.

          5. Neovascularization of the iris.

          6. Uncontrolled glaucoma in either eye (Intraocular Pressure &gt; 24 mmHg).

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Almería</city>
        <state>Andalucía</state>
        <zip>04009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cadiz</city>
        <state>Andalucía</state>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valladolid</city>
        <state>Castilla y Leon</state>
        <zip>47011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Terrassa</city>
        <state>Cataluña</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Laguna</city>
        <state>Las Palmas de Gran Canaria</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barakaldo</city>
        <state>Pais Vasco</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08021</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2009</study_first_submitted>
  <study_first_submitted_qc>May 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2009</study_first_posted>
  <results_first_submitted>May 30, 2014</results_first_submitted>
  <results_first_submitted_qc>May 30, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 3, 2014</results_first_posted>
  <last_update_submitted>February 28, 2017</last_update_submitted>
  <last_update_submitted_qc>February 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Macular Edema</keyword>
  <keyword>Ranibizumab</keyword>
  <keyword>Laser Treatment</keyword>
  <keyword>Visual impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Vision Disorders</mesh_term>
    <mesh_term>Vision, Low</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>RFB002</title>
          <description>RFB002 0.5 mg was administered to the study eye with a single monthly intravitreal injection on day 1, day 30 and day 60. After day 90, if stable vision was not achieved, a monthly injection of RFB002 0.5 mg was administered until stable vision was achieved.</description>
        </group>
        <group group_id="P2">
          <title>Laser Photocoagulation</title>
          <description>At least one treatment of laser photocoagulation was applied on day 1. The maximum number of laser photocoagulation treatments was 4.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="39">One participant did not receive one intravitreal RFB002 injection.</participants>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent to Treat</title>
              <participants_list>
                <participants group_id="P1" count="35">Four treated participants did not have at least a baseline and one post-treatment BCVA.</participants>
                <participants group_id="P2" count="38">Five treated participants did not have at least a baseline and one post-treatment BCVA.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal laboratory values</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administration problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviations</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RFB002</title>
          <description>RFB002 0.5 mg was administered to the study eye with a single monthly intravitreal injection on day 1, day 30 and day 60. After day 90, if stable vision was not achieved, a monthly injection of RFB002 0.5 mg was administered until stable vision was achieved.</description>
        </group>
        <group group_id="B2">
          <title>Laser Photocoagulation</title>
          <description>At least one treatment of laser photocoagulation was applied on day 1. The maximum number of laser photocoagulation treatments was 4.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="82"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.31" spread="8.94"/>
                    <measurement group_id="B2" value="65.47" spread="9.40"/>
                    <measurement group_id="B3" value="63.49" spread="9.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Best Corrected Visual Acuity (BCVA)</title>
        <description>Visual acuity (VA) was assessed on the study eye during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.</description>
        <time_frame>Baseline, 12 months</time_frame>
        <population>Intent-to-treat (ITT): The ITT consisted of all randomized participants who received at least one intravitreal ranibizumab injection of one laser photocoagulation treatment for whom there was at least one baseline and one post-treatment BCVA value. Participants who had both Baseline and Month 12 BCVA values only were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>RFB002</title>
            <description>RFB002 0.5 mg was administered to the study eye with a single monthly intravitreal injection on day 1, day 30 and day 60. After day 90, if stable vision was not achieved, a monthly injection of RFB002 0.5 mg was administered until stable vision was achieved.</description>
          </group>
          <group group_id="O2">
            <title>Laser Photocoagulation</title>
            <description>At least one treatment of laser photocoagulation was applied on day 1. The maximum number of laser photocoagulation treatments was 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Best Corrected Visual Acuity (BCVA)</title>
          <description>Visual acuity (VA) was assessed on the study eye during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.</description>
          <population>Intent-to-treat (ITT): The ITT consisted of all randomized participants who received at least one intravitreal ranibizumab injection of one laser photocoagulation treatment for whom there was at least one baseline and one post-treatment BCVA value. Participants who had both Baseline and Month 12 BCVA values only were included in this analysis.</population>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.41" spread="9.15"/>
                    <measurement group_id="O2" value="5.79" spread="9.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Improvement in BCVA</title>
        <description>Visual acuity (VA) was assessed on the study eye during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.</description>
        <time_frame>12 months</time_frame>
        <population>Intent-to-treat (ITT): The ITT consisted of all randomized participants who received at least one intravitreal ranibizumab injection of one laser photocoagulation treatment for whom there was at least one baseline and one post-treatment BCVA value.</population>
        <group_list>
          <group group_id="O1">
            <title>RFB002</title>
            <description>RFB002 0.5 mg was administered to the study eye with a single monthly intravitreal injection on day 1, day 30 and day 60. After day 90, if stable vision was not achieved, a monthly injection of RFB002 0.5 mg was administered until stable vision was achieved.</description>
          </group>
          <group group_id="O2">
            <title>Laser Photocoagulation</title>
            <description>At least one treatment of laser photocoagulation was applied on day 1. The maximum number of laser photocoagulation treatments was 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Improvement in BCVA</title>
          <description>Visual acuity (VA) was assessed on the study eye during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.</description>
          <population>Intent-to-treat (ITT): The ITT consisted of all randomized participants who received at least one intravitreal ranibizumab injection of one laser photocoagulation treatment for whom there was at least one baseline and one post-treatment BCVA value.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.29"/>
                    <measurement group_id="O2" value="68.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evolution of Mean Change From Baseline in BCVA by Study Visit</title>
        <description>Visual acuity (VA) was assessed on the study eye during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.</description>
        <time_frame>Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12</time_frame>
        <population>ITT: The ITT consisted of all randomized participants who received at least one intravitreal ranibizumab injection of one laser photocoagulation treatment for whom there was at least one baseline and one post-treatment BCVA value. For each month, participants who had both the baseline and the study month BCVA values were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>RFB002</title>
            <description>RFB002 0.5 mg was administered to the study eye with a single monthly intravitreal injection on day 1, day 30 and day 60. After day 90, if stable vision was not achieved, a monthly injection of RFB002 0.5 mg was administered until stable vision was achieved.</description>
          </group>
          <group group_id="O2">
            <title>Laser Photocoagulation</title>
            <description>At least one treatment of laser photocoagulation was applied on day 1. The maximum number of laser photocoagulation treatments was 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Evolution of Mean Change From Baseline in BCVA by Study Visit</title>
          <description>Visual acuity (VA) was assessed on the study eye during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.</description>
          <population>ITT: The ITT consisted of all randomized participants who received at least one intravitreal ranibizumab injection of one laser photocoagulation treatment for whom there was at least one baseline and one post-treatment BCVA value. For each month, participants who had both the baseline and the study month BCVA values were included in the analysis.</population>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 (n=34,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.56" spread="7.38"/>
                    <measurement group_id="O2" value="1.32" spread="7.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 (n=31,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.61" spread="6.55"/>
                    <measurement group_id="O2" value="1.89" spread="8.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=33,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.24" spread="6.41"/>
                    <measurement group_id="O2" value="3.11" spread="7.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4 (n=33,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.33" spread="7.40"/>
                    <measurement group_id="O2" value="2.76" spread="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (n=31,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.03" spread="8.00"/>
                    <measurement group_id="O2" value="3.38" spread="8.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=33,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.61" spread="6.88"/>
                    <measurement group_id="O2" value="4.11" spread="7.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7 (n=33,33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.91" spread="7.16"/>
                    <measurement group_id="O2" value="3.85" spread="7.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8 (n=32,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" spread="7.77"/>
                    <measurement group_id="O2" value="3.21" spread="7.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=32,33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.44" spread="8.78"/>
                    <measurement group_id="O2" value="6.00" spread="9.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (n=31,32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.32" spread="8.17"/>
                    <measurement group_id="O2" value="5.84" spread="9.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 11 (n=32,32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.69" spread="8.88"/>
                    <measurement group_id="O2" value="6.44" spread="8.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=32,33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.41" spread="9.15"/>
                    <measurement group_id="O2" value="5.79" spread="9.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With VA &gt; 73 Letters With Ranibizumab (0.5 mg) vs Laser.</title>
        <description>VA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters.</description>
        <time_frame>12 months</time_frame>
        <population>Intent-to-treat (ITT): The ITT consisted of all randomized participants who received at least one intravitreal ranibizumab injection of one laser photocoagulation treatment for whom there was at least one baseline and one post-treatment BCVA value.</population>
        <group_list>
          <group group_id="O1">
            <title>RFB002</title>
            <description>RFB002 0.5 mg was administered to the study eye with a single monthly intravitreal injection on day 1, day 30 and day 60. After day 90, if stable vision was not achieved, a monthly injection of RFB002 0.5 mg was administered until stable vision was achieved.</description>
          </group>
          <group group_id="O2">
            <title>Laser Photocoagulation</title>
            <description>At least one treatment of laser photocoagulation was applied on day 1. The maximum number of laser photocoagulation treatments was 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With VA &gt; 73 Letters With Ranibizumab (0.5 mg) vs Laser.</title>
          <description>VA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters.</description>
          <population>Intent-to-treat (ITT): The ITT consisted of all randomized participants who received at least one intravitreal ranibizumab injection of one laser photocoagulation treatment for whom there was at least one baseline and one post-treatment BCVA value.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.29"/>
                    <measurement group_id="O2" value="23.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Central Retinal Thickness (CRT) by Study Visit</title>
        <description>CRT was assessed by Optical Coherence Tomography (OCT).</description>
        <time_frame>Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12</time_frame>
        <population>ITT: The ITT consisted of all randomized participants who received at least one intravitreal ranibizumab injection of one laser photocoagulation treatment for whom there was at least one baseline and one post-treatment BCVA value. For each month, participants who had both the baseline and the study month CRT values were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>RFB002</title>
            <description>RFB002 0.5 mg was administered to the study eye with a single monthly intravitreal injection on day 1, day 30 and day 60. After day 90, if stable vision was not achieved, a monthly injection of RFB002 0.5 mg was administered until stable vision was achieved.</description>
          </group>
          <group group_id="O2">
            <title>Laser Photocoagulation</title>
            <description>At least one treatment of laser photocoagulation was applied on day 1. The maximum number of laser photocoagulation treatments was 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Central Retinal Thickness (CRT) by Study Visit</title>
          <description>CRT was assessed by Optical Coherence Tomography (OCT).</description>
          <population>ITT: The ITT consisted of all randomized participants who received at least one intravitreal ranibizumab injection of one laser photocoagulation treatment for whom there was at least one baseline and one post-treatment BCVA value. For each month, participants who had both the baseline and the study month CRT values were included in the analysis.</population>
          <units>micrometers</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 (n=33,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.18" spread="62.23"/>
                    <measurement group_id="O2" value="-21.86" spread="82.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 (n=31,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-69.52" spread="65.10"/>
                    <measurement group_id="O2" value="-14.21" spread="66.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=33,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-80.64" spread="87.06"/>
                    <measurement group_id="O2" value="-43.16" spread="89.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4 (n=33,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-81.79" spread="92.14"/>
                    <measurement group_id="O2" value="-37.66" spread="83.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (n=30,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-77.77" spread="73.47"/>
                    <measurement group_id="O2" value="-28.92" spread="91.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=33,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-93.73" spread="79.42"/>
                    <measurement group_id="O2" value="-40.47" spread="100.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7 (n=33,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-92.76" spread="79.55"/>
                    <measurement group_id="O2" value="-60.94" spread="110.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8 (n=32,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-92.41" spread="82.27"/>
                    <measurement group_id="O2" value="-64.82" spread="110.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=32,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-81.59" spread="81.38"/>
                    <measurement group_id="O2" value="-74.59" spread="112.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (n=31,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-83.32" spread="81.56"/>
                    <measurement group_id="O2" value="-84.39" spread="102.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 11 (n=32,33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-98.03" spread="76.75"/>
                    <measurement group_id="O2" value="-94.85" spread="114.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=32,33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-76.28" spread="76.56"/>
                    <measurement group_id="O2" value="-86.00" spread="115.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of CRT Change From Baseline by Study Visit</title>
        <description>CRT was assessed by Optical Coherence Tomography (OCT).</description>
        <time_frame>Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12</time_frame>
        <population>ITT: The ITT consisted of all randomized participants who received at least one intravitreal ranibizumab injection of one laser photocoagulation treatment for whom there was at least one baseline and one post-treatment BCVA value. For each month, participants who had both the baseline and the study month CRT values were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>RFB002</title>
            <description>RFB002 0.5 mg was administered to the study eye with a single monthly intravitreal injection on day 1, day 30 and day 60. After day 90, if stable vision was not achieved, a monthly injection of RFB002 0.5 mg was administered until stable vision was achieved.</description>
          </group>
          <group group_id="O2">
            <title>Laser Photocoagulation</title>
            <description>At least one treatment of laser photocoagulation was applied on day 1. The maximum number of laser photocoagulation treatments was 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of CRT Change From Baseline by Study Visit</title>
          <description>CRT was assessed by Optical Coherence Tomography (OCT).</description>
          <population>ITT: The ITT consisted of all randomized participants who received at least one intravitreal ranibizumab injection of one laser photocoagulation treatment for whom there was at least one baseline and one post-treatment BCVA value. For each month, participants who had both the baseline and the study month CRT values were included in the analysis.</population>
          <units>Percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 (n=33,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.06" spread="15.16"/>
                    <measurement group_id="O2" value="-3.01" spread="17.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 (n=31,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.61" spread="13.90"/>
                    <measurement group_id="O2" value="-2.20" spread="15.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=33,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.25" spread="17.09"/>
                    <measurement group_id="O2" value="-7.97" spread="17.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4 (n=33,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.00" spread="17.93"/>
                    <measurement group_id="O2" value="-6.99" spread="17.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (n=30,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.21" spread="15.68"/>
                    <measurement group_id="O2" value="-6.39" spread="19.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=33,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.69" spread="15.85"/>
                    <measurement group_id="O2" value="-8.55" spread="21.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7 (n=33,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.11" spread="15.68"/>
                    <measurement group_id="O2" value="-12.50" spread="23.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8 (n=32,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.20" spread="16.43"/>
                    <measurement group_id="O2" value="-13.02" spread="20.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=32,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.17" spread="17.95"/>
                    <measurement group_id="O2" value="-15.68" spread="21.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (n=31,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.55" spread="17.34"/>
                    <measurement group_id="O2" value="-17.24" spread="19.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 11 (n=32,33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.65" spread="15.85"/>
                    <measurement group_id="O2" value="-19.04" spread="22.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=32,33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.23" spread="16.66"/>
                    <measurement group_id="O2" value="-16.59" spread="25.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>RFB002</title>
          <description>RFB002 0.5 mg was administered to the study eye with a single monthly intravitreal injection on day 1, day 30 and day 60. After day 90, if stable vision was not achieved, a monthly injection of RFB002 0.5 mg was administered until stable vision was achieved.</description>
        </group>
        <group group_id="E2">
          <title>Laser Photocoagulation</title>
          <description>At least one treatment of laser photocoagulation was applied on day 1. The maximum number of laser photocoagulation treatments was 4.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Penile cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Necrosis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>1-862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

